Welcome!

News Feed Item

Eisai's R&D Subsidiary Kan Research Institute Commences Full-Scale Operation at New Facility

Aims to Discover and Develop New Biologic Therapies in Kansai International Strategic Innovation Zone

Tokyo, May 26, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced that its research and development subsidiary KAN Research Institute, Inc. (Headquarters: Hyogo Prefecture, President & CEO: Toshio Imai, "KRI") held a dedication ceremony today for its new research facility in Kobe, Hyogo prefecture, and has now officially commenced full-scale operation of its research and development activities at this facility.

KRI is a research group that aims to discover and develop new drugs based on novel therapeutic concepts as a unit of Eisai Product Creation Systems. Specifically, KRI is dedicated to conducting discovery research based on the concept of "Integrative Cell Biology for Medicine" in its three areas of therapeutic focus - refractory immune diseases, neurodegenerative diseases and cancer relapse and metastasis, and aims to discover and develop biologic therapies such as antibodies. Having received official approval from the city of Kobe to take part in a special international strategic development project being implemented within the Kansai International Strategic Innovation Zone, KRI has taken this opportunity to relocate to a new research facility within the Zone in order to strengthen its research capabilities and increase the scale of its research.

The new research facility, located within the Kobe Biomedical Innovation Cluster, has a total floor space of approximately 12,000m2, or roughly five times that of its previous premises, with the capacity to house around 100 researchers, more than twice the present number. With the laboratory specifications allowing for the future installation of an antibody-drug conjugate (ADC) production facility and collaborative lab spaces for external academic and medical researchers, the new research facility has strengthened KRI's antibody research capability while further promoting its open innovation initiatives with external partnerships, one of the core strategies of KRI. These key features of the KRI's new research facility will also contribute to the acceleration of the product creation activities of Eisai as a whole, incorporating state-of-the-art technologies such as those using antibodies and iPS cells into its research. Furthermore, the facility is designed to support business contingency plans in case of a crisis, as it is built using seismic isolation construction methods and is equipped with an emergency electricity generator that can run for up to 72 hours.

With the commencement of full-scale operation at KRI's new facility, Eisai will continue to leverage the advantages established within the Kobe Biomedical Innovation Cluster, one of Japan's largest bioclusters, and partnerships with academic and medical researchers, thereby making further efforts to create new innovative products that increase benefits to patients.

About KAN Research Institute, Inc.

KAN Research Institute, Inc. is a 100% wholly owned research and development subsidiary of Eisai Co., Ltd. It is a research group that aims to discover and develop new drugs based on novel therapeutic concepts within Eisai's research and development system called Eisai Product Creation Systems. Initially established with its strengths in Integrative Cell Biology for Medicine, KRI undertakes drug discovery and research activities that seek to find novel disease mechanisms and treatment paradigms by focusing on the characteristics of specific cell types and molecule localization that cause disease. Located within the Kobe Biomedical Innovation Cluster since 2006, KRI has continued to develop open innovation with research groups and researchers both within and outside the company. Recently, KRI has succeeded in bringing the in-house developed E6011 antibody into clinical development for the potential treatment of inflammatory bowel disease (IBD).

About the Kansai International Strategic Innovation Zone

The "Comprehensive Special Zone" program serves to provide broad comprehensive support tailored to the characteristics of each region for wide-ranging and strategic region-based initiatives designated and accredited under the Comprehensive Special Zone Act of Japan through a range of deregulation, taxation, fiscal, and financial support policies. Relevant government ministries are involved in each of the projects included in the "Accredited Comprehensive Special Zone Plan," and provide targeted financial support by leveraging the budgetary systems over which they have jurisdiction.

As members of the "Kansai International Strategic Innovation Zone," based on this Comprehensive Special Zone Program, Kyoto, Osaka and Hyogo prefectures are working in collaboration with the cities of Kyoto, Osaka and Kobe in an effort to create a structure that promotes the provision of solution-oriented businesses and market expansion initiatives capable of dealing with an aging society, energy problems and other issues that pose a challenge, not only to Japan, but also to countries across all of Asia, in healthcare/medicine and battery-derived energy applications-two areas in which the Kansai area excels.

About Eisai

Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.



Source: Eisai

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Copyright 2014 JCN Newswire. All rights reserved. www.japancorp.net

More Stories By JCN Newswire

Copyright 2008 JCN Newswire. All rights reserved. Republication or redistribution of JCN Newswire content is expressly prohibited without the prior written consent of JCN Newswire. JCN Newswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Interoute has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Interoute is the owner operator of Europe's largest network and a global cloud services platform, which encompasses over 70,000 km of lit fiber, 15 data centers, 17 virtual data centers and 33 colocation centers, with connections to 195 additional partner data centers. Our full-service Unifie...
Most DevOps journeys involve several phases of maturity. Research shows that the inflection point where organizations begin to see maximum value is when they implement tight integration deploying their code to their infrastructure. Success at this level is the last barrier to at-will deployment. Storage, for instance, is more capable than where we read and write data. In his session at @DevOpsSummit at 20th Cloud Expo, Josh Atwell, a Developer Advocate for NetApp, will discuss the role and value...
Cloud applications are seeing a deluge of requests to support the exploding advanced analytics market. “Open analytics” is the emerging strategy to deliver that data through an open data access layer, in the cloud, to be directly consumed by external analytics tools and popular programming languages. An increasing number of data engineers and data scientists use a variety of platforms and advanced analytics languages such as SAS, R, Python and Java, as well as frameworks such as Hadoop and Spark...
IBM helps FinTechs and financial services companies build and monetize cognitive-enabled financial services apps quickly and at scale. Hosted on IBM Bluemix, IBM’s platform builds in customer insights, regulatory compliance analytics and security to help reduce development time and testing. In his session at 20th Cloud Expo, Tom Eck, Industry Platforms CTO at IBM Cloud, will discuss how these tools simplify the time-consuming tasks of selection, mapping and data integration, allowing developers ...
In order to meet the rapidly changing demands of today’s customers, companies are continually forced to redefine their business strategies in order to meet these needs, stay relevant and continue to see profitable growth. IoT deployment and development is integral in this transformation, and today businesses are increasingly seeing the value of investing their resources into IoT deployments. These technologies are able increase ROI through projects such as connecting supply chains or enabling sm...
SYS-CON Events announced today that Progress, a global leader in application development, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Enterprises today are rapidly adopting the cloud, while continuing to retain business-critical/sensitive data inside the firewall. This is creating two separate data silos – one inside the firewall and the other outside the firewall. Cloud ISVs ofte...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
SYS-CON Events announced today that DivvyCloud will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. DivvyCloud software enables organizations to achieve their cloud computing goals by simplifying and automating security, compliance and cost optimization of public and private cloud infrastructure. Using DivvyCloud, customers can leverage programmatic Bots to identify and remediate common cloud problems in rea...
Interested in leveling up on your Cloud Foundry skills? Join IBM for Cloud Foundry Days on June 7 at Cloud Expo New York at the Javits Center in New York City. Cloud Foundry Days is a free half day educational conference and networking event. Come find out why Cloud Foundry is the industry's fastest-growing and most adopted cloud application platform.
For financial firms, the cloud is going to increasingly become a crucial part of dealing with customers over the next five years and beyond, particularly with the growing use and acceptance of virtual currencies. There are new data storage paradigms on the horizon that will deliver secure solutions for storing and moving sensitive financial data around the world without touching terrestrial networks. In his session at 20th Cloud Expo, Cliff Beek, President of Cloud Constellation Corporation, w...
While some vendors scramble to create and sell you a fancy solution for monitoring your spanking new Amazon Lambdas, hear how you can do it on the cheap using just built-in Java APIs yourself. By exploiting a little-known fact that Lambdas aren’t exactly single threaded, you can effectively identify hot spots in your serverless code. In his session at 20th Cloud Expo, David Martin, Principal Product Owner at CA Technologies, will give a live demonstration and code walkthrough, showing how to ov...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
SYS-CON Events announced today that Outscale, a global pure play Infrastructure as a Service provider and strategic partner of Dassault Systèmes, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2010, Outscale simplifies infrastructure complexities and boosts the business agility of its customers. Outscale delivers a secure, reliable and industrial strength solution for its customers, which in...
SYS-CON Events announced today that Cloudistics, an on-premises cloud computing company, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Cloudistics delivers a complete public cloud experience with composable on-premises infrastructures to medium and large enterprises. Its software-defined technology natively converges network, storage, compute, virtualization, and management into a ...
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists will examine how DevOps helps to meet th...